Methylphenidate augmentation of serotonin
selective reuptake inhibitors: a case series
by
Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO
Psycho-pharmacology Unit, Division of Psychiatry,
Brigham and Women's Hospital, Boston, MA 02115, USA.
J Clin Psychiatry 1996 Feb; 57(2):72-6

ABSTRACT

BACKGROUND: The serotonin selective reuptake inhibitors (SSRIs) are effective in treating major depressive episodes. However, for the subgroups of patients who remain refractory to therapy, augmentation strategies can improve the efficacy of these agents. METHOD: We report the results of an open trial of methylphenidate to augment SSRIs in the treatment of five consecutive cases of DSM-III- R diagnosed major depression. RESULTS: Self-reported symptom reduction was achieved rapidly in all cases, with methylphenidate dosages ranging from 10 to 40 mg/day. Symptom remission was independent of the presence of attention-deficit/hyperactivity disorder. Also, the beneficial effects of the methylphenidate-SSRI combination appeared to be robust and sustained. No patients abused or misused methylphenidate. CONCLUSION: The empirical use of methylphenidate added to ineffective or only partially effective SSRI treatment appeared to be a rapid, safe, and efficacious alternative to existing augmentation strategies for the treatment of major depression. Prospective controlled studies are required to confirm or refute these findings.

SSRIs
Options
Recovery
Pergolide
Serotonin
Selegiline
Amineptine
Reboxetine
The Ritalin Kid
Adderall advert
Methylphenidate
Methylphenidate SR
Methylphenidate: profile
Ritalin: long-term effects
Methylphenidate plus citalopram

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family